(Q79572077)
Statements
Early changes in CA125 after treatment with pegylated liposomal doxorubicin or topotecan do not always reflect best response in recurrent ovarian cancer patients (English)
Robert L Coleman
Alan Gordon
James Barter
Steven Sun
Wayne Rackoff
Thomas J Herzog
1 January 2007